SCHEMBL183564

SCHEMBL183564

CS(=O)(=O)Nc1c[c]ccc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.57
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
PGR P06401 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
POLB P06746 1/20 0.41
NR3C2 P08235 3/20 0.41
KIF11 P52732 3/20 0.40
PTGS2 P35354 1/20 0.38
NR3C1 P04150 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2225551 0.81 KIF11 (0.55) KEAP1ALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL5396320 0.81 KEAP1 (0.35) KEAP1CA12CA1CA2CA9
SCHEMBL1157716 0.81 HPGD (0.47) SMN1; SMN2LMNAHPGDHTTPGR
SCHEMBL2224331 0.80 KIF11 (0.54) KEAP1ALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL4210399 0.80 ACP1 (0.36) KEAP1ALDH1A1CA1CA2
SCHEMBL28184919 0.80 CA2 (0.57) CA12CA1CA2CA9KIF11
SCHEMBL789015 0.79 HPGD (0.50) ALDH1A1SMN1; SMN2HPGDHTTPOLB
SCHEMBL1419228 0.79 KDM1A (0.39) KEAP1SMN1; SMN2LMNAPGRCA1
SCHEMBL27617811 0.78 HPGD (0.54) KEAP1ALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL4912270 0.78 PGR (0.49) KEAP1ALDH1A1SMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 US claimed
CN-116234546-A GPX4 inhibitors, pharmaceutical compositions thereof and their use in the treatment of GPX4 mediated diseases 嘉兴优博生物技术有限公司 2023-06-06 CN claimed
CN-113135922-B Azepane [4,3,2-cd ] isoindol-2-one derivatives and application thereof 中国药科大学 2023-05-30 CN claimed
CN-115052604-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2022-09-13 CN claimed
WO-2021183702-A1 GPX4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING GPX4-MEDIATED DISEASES EUBULUS BIOTHERAPEUTICS INC. (CN) 2021-09-16 WO claimed
CN-113135922-A Azacycloheptane [4,3,2-cd ] isoindol-2-one derivatives and application thereof 中国药科大学 2021-07-20 CN claimed
US-20210179612-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-17 US claimed
WO-2021113686-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 WO claimed
CN-112689633-A For inhibiting Nav1.8 pyridine carboxamide Compounds 利伯研究所公司 2021-04-20 CN claimed
CN-111377923-A Pyrido [3',2':6, 7] azepino [4,3,2-cd ] isoindolone derivatives and application thereof 中国药科大学 2020-07-07 CN claimed
WO-2000029377-A1 4-AROYL-PIPERIDIN-CCR-3 RECEPTOR ANTAGONISTS III F. HOFFMANN-LA ROCHE AG (CH) 2000-05-25 WO claimed
EP-0930528-A1 Silver halide photographic light-sensitive material FUJI PHOTO FILM CO., LTD. (JP) 1999-07-21 EP claimed
WO-1997034905-A1 PHOSPHORUS CONTAINING ARYLOXY AND ARYLTHIOPROPANOL AMINE DERIVATIVES USEFUL AS BETA ADRENORECEPTOR AGONISTS SMITHKLINE BEECHAM PLC (GB) 1997-09-25 WO claimed
US-4871765-A GASTROINTESTINAL DISORDERS TOYAMA CHEMICAL CO., LTD. (JP) 1989-10-03 US claimed
US-4338436-A ANTIBIOTICS ELI LILLY AND COMPANY (US) 1982-07-06 US claimed
US-4338439-A BACTERICIDAL ANTIBIOTICS ELI LILLY AND COMPANY (US) 1982-07-06 US claimed
US-4319028-A 7-(2-(Substituted benzoyl)amino)acetamido)cephalosporins ELI LILLY AND COMPANY (US) 1982-03-09 US claimed
US-4248868-A FOR TREATING SYSTEMIC INFECTIONS BY GRAMPOSITIVE AND GRAM NEGATIVE BACTERIA CIBA-GEIGY CORPORATION (US) 1981-02-03 US claimed
EP-0015240-A1 Azacyclyl (thio) ureidoacetyl compounds and their preparation CIBA-GEIGY AG (CH) 1980-09-03 EP claimed
US-4181800-A ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS CSNK1A1, CSNK1D, CSNK1G1 KEAP1 546/4885ALDH1A1 1318/4885SMN1; SMN2 2039/4885
US-20210179612-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 KEAP1 1968/4885ALDH1A1 4709/4885SMN1; SMN2 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.